Home Industry News

Industry News

News from pharmaceutical companies and other related healthcare organizations

On drug and therapy developments for rare diseases

From the desk of Jorge D Faccinetti, Chairman and chief editor - On April 28, the leading orphan drug industry, government and regulatory authorities,...

The Road to MYCAPSSA: A Conversation with Dr. Bill Ludlam

We recently had a chance to sit down with Chiasma Inc.’s Senior VP of Clinical Development & Medical Affairs, Dr. Bill Ludlam, to discuss...

Hello, Pills!

With the recent approval and commercial launch of MYCAPSSA®, Chiasma delivers the first and only oral somatostatin analog to treat acromegaly. The research showed...

Crinetics new drug candidate for acromegaly Paltusotine awarded Orphan Drug Designation

From a Crinetics Pharmaceutical press release:  Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel...

More information on Recordati’s new Cushing’s drug Isturisa

In a recent press release, Recordati Rare Diseases announced the results from a Phase III study of Isturisa® (Osilodrostat) published in Lancet Diabetes and...

More news on Isturisa for Cushing’s

In a recent press release, Recordati Rare Diseases Inc., a biopharmaceutical company committed to developing therapies for rare disease communities of the United States,...

From Endocrine Web: New Oral Acromegaly Treatment Has No Needles Required

From the editors' desk - A recent Endocrine Web article by Kimberly B. Bjugstad Ph.D. highlights a new oral octreotide drug for Acromegaly.  The drug currently...

A new drug for Cushing’s: Learn more

In this podcast, Dr. Lewis Blevins discusses a new drug for Cushing's disease recently approved in the US.  

Exciting news for acromegaly and NET’s from Crinetics Pharmaceuticals!

In a press release today, San Diego, California based Crinetics Pharmaceuticals reports positive results from their Phase Two trial of PALTUSOTINE (the former CRN00808)....

News on Signifor, Signifor LAR, and newly approved Cushing’s drug ISTURISA

Recordati Rare Diseases, Inc., based in Lebanon, NJ, has recently acquired the rights to SIGNIFOR® LAR and the FDA approval for ISTURISA®(osilodrostat). Both products...

NEWS YOU CAN USE

Articles you may like